A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
To evaluate progression-free survival (PFS) in patients with survivin positive newly diagnosed glioblastoma multiforme (GBM) treated with SurVaxM and standard of care temozolomide. PFS is defined as the time from date of diagnosis to the date of first observed disease progression or death due to any cause.
Beth Israel Deaconess Medical Center
Massachusetts General Hospital